Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.
OBJECTIVE
To assess the pharmacokinetic effect and tolerability of lamotrigine 200 mg day(-1) and olanzapine 15 mg day(-1) coadministration in healthy male volunteers.


METHODS
Subjects were randomized to receive either lamotrigine titrated on days 1-42 with olanzapine added on days 43-56 (LTG + OLZ group; N = 16), lamotrigine titration with placebo added on days 43-56 (LTG group; N = 12), or placebo on days 1-42 with olanzapine added on days 43-56 (OLZ group; N = 16). Steady state (0-24 h) pharmacokinetic profiles were determined on day 56 in each group.


RESULTS
The average (90% confidence interval) ratios of lamotrigine area under the concentration-time curve from 0 to 24 h and maximum observed concentration for the comparison of LTG + OLZ:LTG were 0.76 (0.65, 0.90) and 0.80 (0.71, 0.90), respectively. Olanzapine pharmacokinetics were essentially unaffected by lamotrigine. The most frequently reported adverse events (AEs) during combination therapy were fatigue, dizziness and mild transaminase elevations. These AEs occurred at similar frequencies in the LTG + OLZ and OLZ cohorts, while being less frequent or absent in the LTG group.


CONCLUSIONS
Lamotrigine and olanzapine coadministration in patients who may benefit from the combination was supported by this study. Lamotrigine dosing schedules are recommended to remain unchanged when combined with olanzapine therapy. However, the possibility exists that the lamotrigine dose for some patients may need adjustment to optimize treatment when olanzapine is added to or withdrawn from a regimen including lamotrigine.
GlaxoSmithKline Research & Development, Harlow, UK. jssidhu008@hotmail.com
Jagdev
J
Sidhu
Sarah
S
Job
Jonathan
J
Bullman
Emma
E
Francis
Richard
R
Abbott
John
J
Ascher
Jochen G W
JG
Theis
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D001569:Benzodiazepines / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D002491:Central Nervous System Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D000077152:Olanzapine; D014227:Triazines / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002491:Central Nervous System Agents; D014227:Triazines; D001569:Benzodiazepines; D000077152:Olanzapine; D000077213:Lamotrigine